Skip to content

The HYALEX Pivotal Study

The HYALEX Freestyle™ Resurfacing System Pivotal Study: A Multicenter, Single-Arm, Pivotal Study of the HYALEX Freestyle Resurfacing Implant

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06368700
Enrollment
85
Registered
2024-04-16
Start date
2024-04-04
Completion date
2028-12-01
Last updated
2026-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Damaged Chondral or Osteochondral Area

Brief summary

A multicenter, open-label, single-arm, pivotal study to evaluate the safety and effectiveness of the HYALEX Freestyle Resurfacing System for replacement of loss of articular cartilage and bone of the knee femoral condyles in symptomatic patients who require surgical treatment, will be enrolled in the study and undergo implantation of the HYALEX Freestyle Resurfacing Implant.

Interventions

DEVICEHyalex Knee Cartilage System

Surgical implantation of the Hyalex Knee Cartilage System

Sponsors

Hyalex Orthopaedics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

(Phase 1): 1. 22-70 years. 2. Body Mass Index (BMI) ≤ 40. 3. Up to two treatable joint surface lesion, ICRS Grade 3 or 4, located on the medial and/or lateral femoral condyle. 4. Up to 2 implants (one implant per condyle) to treat up to 2 individual symptomatic lesions with a total summative area up to 4.52cm2 / condyle. 5. Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale score between 20 and 65. 6. Ligamentously stable knee. 7. Failure of non-operative treatment (e.g., physical therapy, physician-directed at home exercise program, intra-articular injections, bracing) for at least 4 months prior to consideration for participation in the study.

Exclusion criteria

HYALEX Implant, Surgical Technique, and Lesion Site Exclusions: 1. Known allergy to polyurethanes, bone cement, acrylic, or titanium. 2. Lack of 2mm of cartilage (ICRS Grade 0 to 2) and 2mm of vital bone wall on all sides of the implant site. 3. Osteochondral defect affecting subchondral bone more than 11mm in depth from adjacent non-defect articular surface. 4. Bipolar cartilage lesions involving patellar or tibial lesions ICRS Grade 3 - 4 opposite the lesion intended for treatment. 5. Insufficient bone stock or bone density determined intra-operatively preventing implant press fit. Patient Orthopaedic Health Exclusions: 1. Kellgren and Lawrence (KL) grade 3 or 4 on standing radiographs. 2. Hip-knee-ankle (HKA) angle of greater than +/- 8 degrees (varus or valgus malalignment \> 8 degrees) on standing X-ray. 3. Lack of normally functioning contralateral knee that restricts activity. 4. Recent Osteochondritis Dissecans within 1 year. 5. Diagnosis of a concomitant knee injury which the investigator believes may interfere with study participation or confound effectiveness assessment. 6. Untreated ACL and/or PCL deficiency or complex ligamentous instability of the study knee according to IKDC Grade C (abnormal) or D (severely abnormal). Previous Surgery and Intervention Exclusions: 1. Previous surgical cartilage treatment in the index knee within the last 6 months 2. Previous intra-articular injections, including HA and steroids, within the last 3 months prior to the date of surgery. Patient Overall Health and Health History Exclusions: 1. Any known history of inflammatory arthropathy or untreated or uncontrolled crystal-deposition arthropathy. 2. Current cigarette smoker or user of other nicotine products. 3. Known Type 1 or Type 2 insulin-dependent diabetes mellitus. 4. Currently undergoing immunosuppressive therapy or long-term steroid use (corticosteroid, excluding inhalers) or within 3 months prior to surgery.

Design outcomes

Primary

MeasureTime frameDescription
Composite Primary Endpoint12 months* A clinically significant improvement in KOOS Pain score; * A clinically significant improvement in KOOS ADL score; * Lack of treatment-related SAEs; and * Absence of secondary surgical intervention defined as HYALEX Freestyle Resurfacing Implant removal or revision due to a treatment-related finding.
Change in the Knee Injury & Osteoarthritis Outcome Score (KOOS) at 12 months.12 monthsThe KOOS assesses patient pain, other symptoms, function in daily living, function in sport and recreation, and knee related quality of life. Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms.

Countries

United States

Contacts

CONTACTChris Cain
chris.cain@hyalex.com408-439-5154

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 17, 2026